Psycho-Babble Medication | about biological treatments | Framed
This thread | Show all | Post follow-up | Start new thread | List of forums | Search | FAQ

Re: Any comments regarding sibutramine (Meridia)?

Posted by SLS on July 23, 2006, at 8:23:22

In reply to Re: Any comments regarding sibutramine (Meridia)? » Denise190466, posted by SLS on July 19, 2006, at 19:10:10

Recently, sibutramine has been studied for the treatment of binge-eating disorder. One of the benefits seen in treatment is a reduction in depressive symptomology.


- Scott


A Randomized, Double-blind, Placebo-Controlled Study of Sibutramine in the Treatment of Binge-Eating Disorder
Appolinario JC, Bacaltchuk J, Sichieri R, et al.
Archives of General Psychiatry. 2003;60(11):1109-1116

Binge eating disorder (BED) has been associated with episodes of uncontrolled eating, obesity, and comorbid depressive disorders. Unlike bulimia nervosa, it is not associated with compensatory behaviors such as purging. Antidepressant medications have been the first line of treatment for this disorder. The authors evaluated the efficacy of sibutramine, an antiobesity agent in the treatment of binge eating disorder. They randomly assigned 60 obese outpatients who met the DSM-IV criteria for binge eating disorder to receive either placebo or sibutramine 15 mg/day for 12 weeks. This assignment was done after a 2-week run-in period with placebo, with those patients who maintained 2 or more binge eating episodes during the previous 7 days included in the study. The primary measure of efficacy was the number of days with binge eating episodes during the previous week. Secondary measures included weight, Beck Depression Inventory scores, and Binge Eating Scale scores.

Between baseline and week 2, the sibutramine group showed a sharper reduction in binge eating frequency than the placebo group. This finding was maintained throughout the length of the study. Binge eating days were reduced by 66% in the sibutramine group and 41% in the placebo group. By week 12, those in the sibutramine group experienced a mean weight change of -7.4 kg, while those in the placebo group had a +1.4-kg weight change. Sibutramine also was associated with a significant improvement in depressive symptomatology. In terms of side effects, dry mouth and constipation were significantly higher in the sibutramine group vs the placebo group. The authors concluded that sibutramine is an effective and well-tolerated treatment for binge eating disorder -- for reducing the number of binge days as well as decreasing weight and diminishing comorbid depressive symptomatology.

 

Thread

 

Post a new follow-up

Your message only Include above post


[669630]

Notify the administrators

They will then review this post with the posting guidelines in mind.

To contact them about something other than this post, please use this form instead.

 

Start a new thread

 
Google
dr-bob.org www
Search options and examples
[amazon] for
in

This thread | Show all | Post follow-up | Start new thread | FAQ
Psycho-Babble Medication | Framed

poster:SLS thread:665059
URL: http://www.dr-bob.org/babble/20060717/msgs/669630.html